|Bid||0.00 x 3100|
|Ask||0.00 x 1100|
|Day's Range||18.34 - 18.87|
|52 Week Range||8.39 - 18.87|
|Beta (3Y Monthly)||2.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 27, 2017 - Jul 28, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.27|
Danish pharmaceutical company H. Lundbeck A/S will acquire Alder Biopharmaceuticals for nearly $2 billion in a deal that sent Alder stock rocketing 84% by the stock market's close on Monday.
NEW YORK, Sept. 16, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Alder BioPharmaceuticals, Inc. (ALDR) on behalf of Alder shareholders concerning the proposed merger with H. Lundbeck A/S. Pursuant to the proposed transaction, announced on September 16, 2019 and valued at up to $1.95 billion, Alder shareholders will receive $18 in cash and a non-tradeable Contingent Value Right for each share of Alder common stock owned. The Contingent Value Right entitles Alder shareholders to an additional $2 in cash for each share of Alder common stock owned pending the approval of eptinezumab by the European Medicines Agency. The investigation focuses on whether Alder and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company's shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Yuma Energy (AMEX: YUMA) shares were up 53.8% ...
WILMINGTON, DE / ACCESSWIRE / September 16, 2019 / Rigrodsky & Long, P.A.: Do you own shares of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR )? Did you purchase any of your shares prior to September 16, ...
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Alder BioPharmaceuticals, Inc. (ALDR) to H. Lundbeck A/S (“Lundbeck”) is fair to Alder shareholders. On behalf of Alder shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. If you are an Alder shareholder and would like to discuss your legal rights and options, please visit Alder BioPharmaceuticals Merger or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or firstname.lastname@example.org or email@example.com.
MILWAUKEE , Sept. 16, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating Alder (Nasdaq: ALDR) for possible breaches of fiduciary duty and other violations of the law in connection with the sale ...
NEW YORK, Sept. 16, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Alder BioPharmaceuticals, Inc..
Alder shareholders will receive $18 per share in cash as part of the deal, along with one tradeable contingent value right that entitles them to receive an additional $2 per share upon approval of eptinezumab — a Phase 3 migraine prevention drug candidate — by the European Medicines Agency. This renders the total consideration to $20 per share, with a total transaction value of $1.95 billion net of cash on a fully diluted basis. The upfront cash payment of $18 per share represents a 79% premium to the Sept. 13 closing price of Alder shares.
Shares of Alder BioPharmaceuticals Inc. blasted 83% higher on very heavy volume in premarket trading Monday, after the developer of migraine treatment eptinezumab agreed to be bought out by Denmark-based H. Lundbeck A/S in a deal valued at $1.95 billion. Trading volume was already more than 4.6 million shares an hour ahead of the open, compared with the full-day average of about 638,000 shares. Under terms of the deal, Lundbeck will commence a tender offer of $18 for each Alder share outstanding, which is 79% above Friday's closing price of $10.06. Alder shareholders will also receive a contingent value right (CVR) that entitles them to an additional $2 a share if Alder's eptinezumab is approved by the European Medicines Agency (EMA). At $20 a share, Alder's market capitalization would be $1.67 billion. Alder's stock hasn't closed at $20 or above since May 2017. The stock has lost 44.7% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has lost 11.5% and the S&P 500 has gained 3.5%.
SAN DIEGO, Sept. 16, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Alder BioPharmaceuticals, Inc. (ALDR) ("Alder") breached their fiduciary duties in connection with the proposed sale of the Company to Danish pharmaceutical company Lundbeck. On September 16, 2019, Alder announced that it had signed a definitive merger agreement with Lundbeck. The investigation concerns whether the Alder board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Alder shares of common stock.
Alder Biopharmaceuticals surges after rival Danish drugmaker Lundbeck announces plans to acquire the company and its late-stage migraine drug eptinezumab in a deal worth up to $1.95 billion.
Danish pharmaceutical company Lundbeck will acquire Alder BioPharmaceuticals in a deal valued at almost $2 billion, the company said in a statement on Monday. The deal, expected to close in the fourth quarter of this year, will be funded through existing cash resources and bank financing, Lundbeck said. Lundbeck will buy outstanding shares of Alders in an upfront payment of $18 per share.
Enhances Lundbeck’s leading portfolio of brain disease therapies with Alder’s highly complementary intravenous (IV) therapy for migraine prevention, eptinezumabEptinezumab is an.
Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing therapeutic antibodies for the treatment of migraine, today announced that it will present data from its migraine prevention portfolio including two late-breaking presentations at IHC 2019, the 19th Congress of the International Headache Society, in Dublin, Ireland, being held from September 5-8, 2019. The data presentations will feature pharmacokinetic, efficacy and quality of life analyses from clinical trials for eptinezumab, an investigational monoclonal antibody (mAb) developed for the prevention of migraine and delivered by quarterly IV administration, and an evaluation of binding properties for ALD1910, Alder’s preclinical mAb also developed for the prevention of migraine.
REDWOOD CITY, Calif., Sept. 4, 2019 /PRNewswire/ -- Bolt Biotherapeutics, Inc., a private biotechnology company focused on unleashing the power of the immune system to treat cancer, today announced that it has appointed Randall Schatzman, Ph.D. to the position of chief executive officer and as a member of Bolt's board of directors. Dr. Schatzman brings over 30 years of biotech leadership experience to Bolt and most recently served as president and CEO of Alder BioPharmaceuticals, Inc. where he successfully led the company from inception through registration-enabling activities including positive Phase 3 trials and significant fund raising.
BOTHELL, Wash., Aug. 30, 2019 -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment.
BOTHELL, Wash., Aug. 28, 2019 -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment.
MyoKardia (MYOK) doses the first patient in phase I study on MYK-224, which is being evaluated for treating patients with hypertrophic cardiomyopathy, a common heart disease.
NuCana (NCNA) suspends patient enrollment in the phase III study on Acelarin, currently evaluated for treating patients with metastatic pancreatic cancer, who were unfit for combination chemotherapy.
On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility.
Data presented at American Academy of Neurology and American Headache Society Annual Meetings continue to support eptinezumab’s differentiated clinical profile and impact on.
Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder’s Board of Directors granted a non-qualified stock option to purchase an aggregate of 45,000 shares of Alder’s common stock and an award of 25,000 restricted stock units (“RSUs”) to a new employee under Alder’s 2018 Inducement Award Plan (the “Inducement Plan”), effective July 29, 2019 (the “Grant Date”), and another aggregate of 178,300 RSUs to 28 other new employees under the Inducement Plan, effective July 30, 2019.